Production (Stage)
Syros Pharmaceuticals, Inc.
SYRS
$0.03
-$0.0008-2.60%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -97.82M | -131.56M | -144.49M | -164.57M | -104.96M |
| Total Depreciation and Amortization | 1.34M | 1.63M | 1.95M | 2.25M | 2.61M |
| Total Amortization of Deferred Charges | 570.00K | 566.00K | 591.00K | 574.00K | 559.00K |
| Total Other Non-Cash Items | -7.50M | 20.50M | 28.66M | 46.99M | -19.82M |
| Change in Net Operating Assets | 3.38M | -2.32M | 9.40M | 5.06M | -608.00K |
| Cash from Operations | -100.02M | -111.19M | -103.90M | -109.71M | -122.23M |
| Capital Expenditure | -38.00K | -38.00K | -37.00K | -272.00K | -908.00K |
| Sale of Property, Plant, and Equipment | 1.69M | 1.69M | 1.59M | 1.56M | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 302.00K | 28.94M | 36.89M | 36.05M | 74.44M |
| Cash from Investing | 1.95M | 30.59M | 38.45M | 37.34M | 73.54M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -3.00K | -8.00K | -12.00K | -65.00K | -137.00K |
| Issuance of Common Stock | 43.50M | 43.50M | 43.53M | 43.53M | 144.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -8.20M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -339.00K | -339.00K | -265.00K | -- | -2.43M |
| Cash from Financing | 43.16M | 43.15M | 43.25M | 43.46M | -10.62M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -54.91M | -37.45M | -22.21M | -28.91M | -59.31M |